Magic mushrooms and 'toad venom' get this British biotech an oversubscribed Series B

Max Gelman

Senior Editor

A new psychedelics player burst onto the scene Monday with a hefty Series B, aiming to refashion two well-known drugs into therapies for crippling headaches …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Magic mushrooms and 'toad venom' get this British biotech an oversubscribed Series B

Max Gelman

Senior Editor

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

'Go ahead and do it': Top RFK Jr. deputy dares drugmakers that might pull manufacturing over new price pressure

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

New CBER chief Prasad is readying 'massive framework' around vaccines, Makary says

Eli Lilly turns to South Korean RNA editing biotech for hearing loss in deal worth $1.3B

Bristol Myers CEO says America’s biopharma pole position is not guaranteed

Exclusive: Drug compounder Empower was built on risky shortcuts, ex-employees and inspections allege

Mag­ic mush­rooms and 'toad ven­om' get this British biotech an over­sub­scribed Se­ries B

Senior Editor

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Magic mushrooms and 'toad venom' get this British biotech an oversubscribed Series B